The potencies of edrophonium and neostigmine as antagonists of pancuronium.
Dose response curves were constructed for edrophonium and neostigmine when used to antagonise pancuronium, 0.07 mg/kg during thiopentone-nitrous oxide-halothane anaesthesia. The antagonist was given when 10% twitch height had been restored and the effect was measured 10 minutes later. Recoveries to 50% and 90% twitch height were achieved with 167 and 828 micrograms/kg of edrophonium, and 10.5 and 51 micrograms/kg of neostigmine. The dose response curves were parallel and neostigmine was 16 times more potent than edrophonium. Combinations of equipotent doses of edrophonium and neostigmine were also administered and produced additive but not synergistic effects. It is concluded that either edrophonium or neostigmine may be used for the reversal of pancuronium neuromuscular blockade, but the combination of the two offers no advantage.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004491:Edrophonium / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology*; D010197:Pancuronium / Q000037:antagonists & inhibitors*; D013810:Therapeutic Equivalency
D004338:Drug Combinations; D009388:Neostigmine; D004491:Edrophonium; D010197:Pancuronium